Abstract
Objective:
Antenatal exposure to methadone or buprenorphine often causes neonatal abstinence syndrome (NAS) in newborns. However, comparative effects on affected infants’ hospital courses are inconclusive. We sought to estimate the relationship of antenatal exposure with methadone or buprenorphine and infants’ length of stay among hospitalized infants with NAS.
Study Design:
This was a retrospective cohort study of hospitalized infants with NAS with either maternal exposure. Eligible infants were singleton infants born ⩾36 weeks’ gestation and diagnosed with NAS<7 days of age between 2011 and 2014 in the Pediatrix Clinical Data Warehouse. Infant with congenital anomalies and those of multiple gestation were excluded.
Results:
Of 3364 eligible infants, 2202 (65%) were exposed to methadone and 1162 (34%) to buprenorphine. Infants exposed to buprenorphine had a lower rate of pharmacologic treatment for NAS (88 vs 91%, P<0.001). Median length of hospital stay was shorter among infants exposed to buprenorphine (21 days (inter-quartile range; 13–31) vs methadone (24 days (15–38), P<0.0001)). On multivariable Cox proportional hazard analyses, buprenorphine was associated with a shorter length of stay (hazard ratio (HR)=1.47 (95% confidence interval (CI): 1.32–1.62, P<0.001) after controlling for maternal age, parity, race or ethnicity, prenatal care, smoking status, use of antidepressants, use of benzodiazepines, and infant gestational age, small for gestational age status, cesarean delivery, sex, out born status, type of pharmacotherapy, breast milk use, year and center. We observed similar results in model using infants matched 1:1 with propensity scores for antenatal medication exposure (HR 1.39 for buprenorphine, CI 1.32–1.62, P<0.001).
Conclusion:
Among infants born ⩾36 weeks’ gestation with NAS, antenatal buprenorphine exposure was associated with a decreased length of stay relative to antenatal methadone exposure.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hudak ML, Tan RC . Neonatal drug withdrawal. Pediatrics 2012; 129 (2): e540–e560.
Patrick SW, Schumacher RE, Benneyworth BD, Krans EE, McAllister JM, Davis MM . Neonatal abstinence syndrome and associated health care expenditures: United States, 2000–2009. JAMA 2012; 307 (18): 1934–1940.
Patrick SW, Davis MM, Lehmann CU, Cooper WO . Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012. J Perinatol 2015; 35 (8): 650–655.
Tolia VN, Patrick SW, Bennett MM, Murthy K, Sousa J, Smith PB et al. Increasing incidence of the neonatal abstinence syndrome in U.S. neonatal ICUs. N Engl J Med 2015; 372 (22): 2118–2126.
ACOG Committee on Health Care for Underserved Women; American Society of Addiction Medicine. Opioid abuse, dependence, and addiction in pregnancy. Committee Opinion No. 524. American College of Obstetricians and Gynecologists. Obstet Gynecol 2012; 119: 1070–1076.
Noormohammadi A, Forinash A, Yancey A, Crannage E, Campbell K, Shyken J . Buprenorphine versus methadone for opioid dependence in pregnancy. Ann Pharmacother 2016; 50 (8): 666–672.
Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010; 363 (24): 2320–2331.
Minozzi S, Amato L, Bellisario C, Ferri M, Davoli M . Maintenance agonist treatments for opiate-dependent pregnant women. Cochrane Database Syst Rev 2013; (12): CD006318.
Lacroix I, Berrebi A, Garipuy D, Schmitt L, Hammou Y, Chaumerliac C et al. Buprenorphine versus methadone in pregnant opioid-dependent women: a prospective multicenter study. Eur J Clin Pharmacol 2011; 67 (10): 1053–1059.
Welle-Strand GK, Skurtveit S, Jones HE, Waal H, Bakstad B, Bjarkø L et al. Neonatal outcomes following in utero exposure to methadone or buprenorphine: a National Cohort Study of opioid-agonist treatment of pregnant women in Norway from 1996 to 2009. Drug Alcohol Depend 2013; 127 (1-3): 200–206.
Gordon AL, Lopatko OV, Haslam RR, Stacey H, Pearson V, Woods A et al. Ineffective morphine treatment regimen for the control of Neonatal Abstinence Syndrome in buprenorphine- and methadone-exposed infants. J Dev Orig Health Dis 2012; 3 (4): 262–270.
Nørgaard M, Nielsson MS, Heide-Jørgensen U . Birth and neonatal outcomes following opioid use in pregnancy: a danish population-based study. Subst Abuse 2015; 9 (Suppl 2): 5–11.
Meyer MC, Johnston AM, Crocker AM, Heil SH . Methadone and buprenorphine for opioid dependence during pregnancy: a retrospective cohort study. J Addict Med 2015; 9 (2): 81–86.
Wiegand SL, Stringer EM, Stuebe AM, Jones H, Seashore C, Thorp J . Buprenorphine and naloxone compared with methadone treatment in pregnancy. Obstet Gynecol 2015; 125 (2): 363–368.
Spitzer AR, Ellsbury DL, Handler D, Clark RH . The Pediatrix BabySteps Data Warehouse and the Pediatrix QualitySteps improvement project system—tools for ‘meaningful use’ in continuous quality improvement. Clin Perinatol 2010; 37 (1): 49–70.
Olsen IE, Groveman SA, Lawson ML, Clark RH, Zemel BS . New intrauterine growth curves based on United States data. Pediatrics 2010; 125 (2): e214–e224.
Williams RL . A note on robust variance estimation for cluster-correlated data. Biometrics 2000; 56 (2): 645–646.
Curtis LH, Hammill BG, Eisenstein EL, Kramer JM, Anstrom KJ . Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases. Med Care 2007; 45 (10 Suppl 2): S103–S107.
Pencina MJ, D'Agostino RB . Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 2004; 23 (13): 2109–2123.
Brown MS, Hayes MJ, Thornton LM . Methadone versus morphine for treatment of neonatal abstinence syndrome: a prospective randomized clinical trial. J Perinatol 2015; 35 (4): 278–283.
Kocherlakota P . Neonatal abstinence syndrome. Pediatrics 2014; 134 (2): e547–e561.
Patrick SW, Schumacher RE, Horbar JD, Buus-Frank ME, Edwards EM, Morrow KA et al. Improving care for neonatal abstinence syndrome. Pediatrics 2016; 137: e20153835.
Hall ES, Wexelblatt SL, Crowley M, Grow JL, Jasin LR, Klebanoff MA et al. A multicenter cohort study of treatments and hospital outcomes in neonatal abstinence syndrome. Pediatrics 2014; 134 (2): e527–e534.
Patrick SW, Kaplan HC, Passarella M, Davis MM, Lorch SA . Variation in treatment of neonatal abstinence syndrome in US children's hospitals, 2004–2011. J Perinatol 2014; 34 (11): 867–872.
Gaalema DE, Scott TL, Heil SH, Coyle MG, Kaltenbach K, Badger GJ et al. Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. Addiction 2012; 107 (Suppl 1): 53–62.
Brogly SB, Hahn KA, Diaz SH, Werler M . Confounding of the comparative safety of prenatal opioid agonist therapy. J Addict Res Ther 2015; 6: pii: 252.
Zedler BK, Mann AL, Kim MM, Amick HR, Joyce AR, Murrelle EL et al. Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta-analysis of safety in the mother, fetus and child. Addiction 2016; 111: 2115–2128.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Journal of Perinatology website
Supplementary information
Rights and permissions
About this article
Cite this article
Tolia, V., Murthy, K., Bennett, M. et al. Antenatal methadone vs buprenorphine exposure and length of hospital stay in infants admitted to the intensive care unit with neonatal abstinence syndrome. J Perinatol 38, 75–79 (2018). https://doi.org/10.1038/jp.2017.157
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/jp.2017.157
This article is cited by
-
The Influence of Mediators on the Relationship Between Antenatal Opioid Agonist Exposure and the Severity of Neonatal Opioid Withdrawal Syndrome
Maternal and Child Health Journal (2023)
-
Racial differences in opioid withdrawal syndrome among neonates with intrauterine opioid exposure
Pediatric Research (2021)